Efficacy and onset of action of @entity7496 2.5% and @entity61420 1% lotion for the management of XXXX : results of a pilot study.

@entity1 @entity7496 @entity111 @entity61420 @entity19157 @entity130
@entity19157 is the most common symptom among @entity1 presenting to the dermatology clinic. Scratching can cause mechanical @entity130 to the skin, further damaging the epidermal barrier and its function. This damage can facilitate the introduction of microbes that complicate the presenting disease and its management. @entity111 has a negative influence on quality of life. Initiation of treatment that can safely and effectively manage @entity111 may provide immediate benefits to the @entity1 . A novel topical formulation of @entity7496 2.5% and @entity61420 1% in a hydrophilic lotion base is indicated for the management of @entity111 . However, the rate of onset of antipruritic effects has not been well studied. This single-center, open-label, pilot study involved 11 subjects age 18 and older. All subjects applied @entity7496 2.5% and @entity61420 1% lotion four times daily for one day. Severity of @entity19157 as measured by the visual analog scale decreased significantly following one day of medication use. The change in mean visual analog scale from baseline was -2.16  2.78 (P=0.0275), representing a mean percentage reduction of 31.74  42.11 (P=0.0315). Topical application of @entity7496 2.5% and @entity61420 1% lotion provides a significant reduction in @entity111 as rated by @entity1 using the visual analog scale with a single day of use. Early onset of action to decrease @entity19157 is expected to improve the @entity1 's treatment experience and increase the level of long-term adherence.
